Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAdOx1-HBV in Healthy and Chronic HepB Participants
NCT04297917Phase 1Completed
- Sponsor
- Barinthus Biotherapeutics
- Start
- Feb 2019
- Primary completion
- May 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdOx1-HBV in Chronic Hepatitis B (CHB) (6 arms), sponsored by Barinthus Biotherapeutics. Primary endpoints: Incidence of Safety and Reactogenicity Events: Adverse Events at Day 168, Incidence of Safety and Reactogenicity Events: Serious Adverse Events at Day 168 and 3 more. Started Feb 2019; status: completed.
02
Drugs
ChAdOx1-HBV
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04297917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297917.